Literature DB >> 31641552

Splenic oligometastasis: Report of a patient successfully treated with stereotactic body radiation therapy.

Aditya Juloori1, Shireen Parsai1, Kevin Stephans1.   

Abstract

The use of SRS/SBRT has been extensively reported on for tumors of the lung, liver, pancreas, adrenal gland, brain, and spine. Tumor control and associated toxicities of treatment are well understood and the use of SBRT in these sites is well-accepted. Here we uniquely report a detailed case of SBRT to the spleen and demonstrate pre- and post-treatment imaging along with treatment planning implications. We demonstrate excellent local control at 4 year follow-up with no development of late toxicity.
© 2019 Old City Publishing, Inc.

Entities:  

Keywords:  Spleen; oligometastasis; stereotactic body radiation therapy

Year:  2019        PMID: 31641552      PMCID: PMC6774496     

Source DB:  PubMed          Journal:  J Radiosurg SBRT


  7 in total

1.  Patterns of metastatic cancer in the spleen.

Authors:  J H MARYMONT; S GROSS
Journal:  Am J Clin Pathol       Date:  1963-07       Impact factor: 2.493

2.  Splenectomy for splenic metastases: a changing clinical spectrum.

Authors:  S S Lee; L Morgenstern; E H Phillips; J R Hiatt; D R Margulies
Journal:  Am Surg       Date:  2000-09       Impact factor: 0.688

Review 3.  Splenic irradiation for splenomegaly: A systematic review.

Authors:  Nicholas G Zaorsky; Graeme R Williams; Stefan K Barta; Nestor F Esnaola; Patricia L Kropf; Shelly B Hayes; Joshua E Meyer
Journal:  Cancer Treat Rev       Date:  2016-12-22       Impact factor: 12.111

4.  Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up.

Authors:  Sigurdur Y Kristinsson; Gloria Gridley; Robert N Hoover; David Check; Ola Landgren
Journal:  Haematologica       Date:  2013-09-20       Impact factor: 9.941

5.  Clinical outcomes and dosimetric considerations using stereotactic body radiotherapy for abdominopelvic tumors.

Authors:  Brandon M Barney; Kenneth R Olivier; O Kenneth Macdonald; Luis E Fong de Los Santos; Robert C Miller; Michael G Haddock
Journal:  Am J Clin Oncol       Date:  2012-12       Impact factor: 2.339

6.  Non-small cell lung cancer stage IV long-term survival with isolated spleen metastasis.

Authors:  Rodrigo A S Sardenberg; Clovis Pinto; Cynthia A Bueno; Riad N Younes
Journal:  Ann Thorac Surg       Date:  2013-04       Impact factor: 4.330

7.  Splenic metastases in a large unselected autopsy series.

Authors:  Corinna Ariane Schön; Christian Görg; Annette Ramaswamy; Peter J Barth
Journal:  Pathol Res Pract       Date:  2006-02-20       Impact factor: 3.250

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.